MedTrace Logo

Network Pharmacology Prediction: Mechanism Study of Puerarin in the Treatment of Giant Cell Tumors of Bone

NCT06331104 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 145

Last updated 2024-04-02

No results posted yet for this study

Summary

Based on network pharmacology analysis, this study aims to explore the potential therapeutic targets and molecular mechanisms of puerarin on giant cell tumor of bone (GCTB) genes.

Conditions

  • Giant Cell Tumors

Interventions

GENETIC

gene expression levels

12 immunohistochemical sections were scored under the microscope (staining intensity scores: negative 0 points, weak 1 point, medium 2 points, strong 3 points; positive cell frequency scores: less than 5% 0 points, 2-25% 1 point, 26-50% 2 points, 51-75% 3 points, greater than 75% 4 points).

Sponsors & Collaborators

  • Changye Zou

    lead OTHER

Principal Investigators

  • Changye Zou, MD · First Affiliated Hospital, Sun Yat-Sen University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-14
Primary Completion
2023-08-31
Completion
2023-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06331104 on ClinicalTrials.gov